ARS Pharmaceuticals, Inc.
SPRY
$14.05
$0.816.12%
| Weiss Ratings | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.10 | |||
| Price History | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.66% | |||
| 30-Day Total Return | 34.06% | |||
| 60-Day Total Return | 16.99% | |||
| 90-Day Total Return | -3.17% | |||
| Year to Date Total Return | 31.19% | |||
| 1-Year Total Return | 52.06% | |||
| 2-Year Total Return | 135.74% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -28.47% | |||
| 52-Week Low % Change | 75.36% | |||
| Price | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.51 | |||
| 52-Week Low Price | $7.55 | |||
| 52-Week Low Price (Date) | Jun 25, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.30B | |||
| Enterprise Value | 1.05B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -97.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 17.71 | |||
| Price/Book (Q) | 5.05 | |||
| Enterprise Value/Revenue (TTM) | 11.83 | |||
| Price | $14.05 | |||
| Enterprise Value/EBITDA (TTM) | -351.04 | |||
| Enterprise Value/EBIT | -342.04 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 119.21M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 771 9307 | |||
| Address | 11682 El Camino Real San Diego, CA 92130 | |||
| Website | ars-pharma.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3.45% | |||
| Profit Margin | 8.97% | |||
| Management Effectiveness | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -0.66% | |||
| Return on Equity | 3.28% | |||
| Income Statement | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 89.15M | |||
| Total Revenue (TTM) | 89.15M | |||
| Revenue Per Share | $0.75 | |||
| Gross Profit (TTM) | 68.79M | |||
| EBITDA (TTM) | -3.00M | |||
| EBIT (TTM) | -3.08M | |||
| Net Income (TTM) | 8.00M | |||
| Net Income Avl. to Common (TTM) | 8.00M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 796.62% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 663.67% | |||
| Balance Sheet | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 314.02M | |||
| Cash Per Share (Q) | $2.63 | |||
| Total Current Assets (Q) | 334.30M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 256.80M | |||
| Current Ratio (Q) | 14.262 | |||
| Book Value Per Share (Q) | $2.62 | |||
| Total Assets (Q) | 351.15M | |||
| Total Current Liabilities (Q) | 23.44M | |||
| Total Debt (Q) | 69.43M | |||
| Total Liabilities (Q) | 94.36M | |||
| Total Common Equity (Q) | 256.80M | |||
| Cash Flow | SPRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -106.10M | |||
| Cash from Financing (TTM) | 72.40M | |||
| Net Change in Cash (TTM) | -20.15M | |||
| Levered Free Cash Flow (TTM) | 8.96M | |||
| Cash from Operations (TTM) | 13.55M | |||
